CONSTITUENT REPORT
(Z)-Tagetenone
(Z)-Tagetenone is an unsaturated Tagetes monoterpene ketone also commonly listed as cis-ocimenone in reference chemistry sources. The live evidence base in this pass supports its identity and repeated occurrence as a major constituent of Tagetes oils, but direct isolated-compound bioactivity evidence was limited. In the archive, it is most defensible to present (Z)-tagetenone as a chemotype-defining aroma molecule with mixture-level links to antimicrobial and biocidal Tagetes-oil research, while keeping explicit gaps around standalone safety and human data.
Chemical identity and composition
NIST lists cis-tagetenone and (Z)-2,6-dimethylocta-2,5,7-trien-4-one as the same structure with formula C10H14O, and supplier-reference pages align the common aliases cis-tagetenone and (Z)-ocimenone. Tagetes oils can contain both Z and E tagetenone isomers, and several composition papers place the Z isomer among the dominant oxygenated monoterpenes in capitula, leaf, or whole-aerial-part oils.
Aroma and practical use
- Use the recorded green, herbal, fruity, tagetes-like, penetrating, herbaceous descriptors to explore a blend's scent character; perceived strength also depends on the other ingredients.
- Read the route, preparation and experimental context before using a study finding to choose an oil.
Reported benefits and effects
Findings retain their study context. An animal or laboratory result describes that experiment.
A 2020 Industrial Crops and Products abstract on Himalayan Tagetes minuta reported that oil quality varies by chemotype and noted that tagetenone is essential for biocidal activity, supporting a mixture-level association rather than isolated-compound proof.
A 2020 Industrial Crops and Products abstract on Himalayan Tagetes minuta reported that oil quality varies by chemotype and noted that tagetenone is essential for biocidal activity, supporting a mixture-level association rather than isolated-compound proof.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
A 2002 composition study of Tagetes patula reported (Z)-tagetenone at 12.4% in capitula oil and 5.5% in leaf oil, supporting its status as a recurrent major constituent rather than a rare trace molecule.
A 2002 composition study of Tagetes patula reported (Z)-tagetenone at 12.4% in capitula oil and 5.5% in leaf oil, supporting its status as a recurrent major constituent rather than a rare trace molecule.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
Use concerns and concentration limits
Sensitization concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Phototoxicity concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Oxidation concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Penetration enhancementNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
A recorded constituent reference, not a recommended oil dilution. Product category, source applicability and all contributing oils must be checked before use.
unverified reference · No source provenance attachedNo constituent-specific human safety trial, dermal limit, or phototoxicity threshold for isolated (Z)-tagetenone was verified in this pass.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
Because accessible activity data are mostly whole-oil or chemotype-level, efficacy language for isolated (Z)-tagetenone should stay conservative and non-medical.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
Constituents it may interact with
These are research candidates recorded in the interaction matrix. They do not add a proven-amplification bonus to the score.
(Z)-TagetoneAmplification candidate
Candidate in the research matrix. A coefficient alone does not establish amplification at the dose, route or goal of your blend; no proven amplification is inferred from this row.
review · whole_oil
No source citation attached.
Read (Z)-Tagetone report →What this report cannot establish
- A reported constituent percentage does not establish an effective human therapeutic dose or the amount absorbed into the body.
- The presence of a constituent does not guarantee a clinical benefit, rash treatment or sleep improvement from a custom blend.
- An unflagged concern or missing use limit does not establish safety for ingestion, inhalation, skin exposure or a particular person.
- A candidate constituent interaction does not establish that two oils amplify one another at the selected proportions.
- Constituent descriptors alone do not establish a precise top, heart or base lifetime in a finished blend.
Known data gaps (6)
- Direct isolated-compound bioactivity literature for (Z)-tagetenone was limited in this pass; most accessible evidence is chemotype or whole-oil based.
- This pass did not verify a human study or constituent-specific toxicology review for isolated (Z)-tagetenone.
- Published naming can alternate between tagetenone and ocimenone conventions, so synonym mapping needs care when comparing databases.
- The numeric dermal reference lacks source provenance; a verified flag alone is insufficient.
- Some findings do not record an explicit exposure route; consult the linked study before applying them to a use.
- Interaction candidates lack an attached source citation and remain unqualified.